Exchange: NASDAQ·Updated 08:00 AM EDT

DNLI News

News
all
press releases
Klotho Protein Emerges as a Potential Powerhouse In the Next Generation of Longevity Medicine
Human clinical development is putting one of aging biology’s most closely watched proteins on the biotechnology radar   New York, NY – September 30, 2026 – Klotho is quickly becoming one of the more interesting names in longevity research. What started largely as a research question around aging and biological decline is now moving closer […] The post Klotho Protein Emerges as a Potential Powerhouse In the Next Generation of Longevity Medicine appeared first on Financial News Media.
Financial News Media
Klotho Protein Emerges as a Potential Powerhouse In the Next Generation of Longevity Medicine
Human clinical development is putting one of aging biology’s most closely watched proteins on the biotechnology radar   New York, NY – September 30, 2026 – Klotho is quickly becoming one of the more interesting names in longevity research. What started largely as a research question around aging and biological decline is now moving closer […] The post Klotho Protein Emerges as a Potential Powerhouse In the Next Generation of Longevity Medicine appeared first on Financial News Media.
Financial News Media
More News
DNLI Stock Gains 33.1% in Three Months: Buy, Sell or Hold the Stock?
Denali's Avlayah launch drives strong uptake and a 33.1% three-month stock gain, but regulatory and pipeline risks remain.
Zacks
Should You Buy, Sell or Hold Biogen Stock After a 9% Rise in a Month?
BIIB's newer drugs, M&A activity and pipeline progress are fueling its turnaround, but declining MS sales remain a key risk.
Zacks
Denali Therapeutics (DNLI) Q2 2026 Earnings Call Transcript
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...
Nasdaq News: Markets
DNLI Q2 Loss Narrows, Avlayah Sales Drive Strong Launch Momentum
Denali Therapeutics narrows Q2 loss as Avlayah sales top estimates, with strong launch traction and pipeline updates shaping its outlook.
Zacks
Denali Therapeutics Inc. (DNLI) Reports Q2 Loss, Tops Revenue Estimates
Denali Therapeutics (DNLI) delivered earnings and revenue surprises of +5.56% and +143.35%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Will Recent Setbacks Impact Growth Prospects of DNLI Stock?
Denali Therapeutics gains FDA approval for Avlayah, but pipeline setbacks and partner exits raise fresh questions as key clinical programs continue.
Zacks
DNLI Stock Surges 59.4% Year to Date: Is There More Room for Growth?
Denali Therapeutics surges on Avlayah???s FDA approval, PRV sale and pipeline progress, but partnership changes and trial setbacks remain in focus.
Zacks
Regenxbio Shares Rise on Plans to Resubmit Navsunli BLA for MPS II
RGNX shares jump after FDA alignment on next steps for Navsunli, paving the way for a planned MPS II BLA resubmission in Q3 2026.
Zacks
Denali to Sell Priority Review Voucher for $195M Cash Boost
DNLI will gain $195M from selling its Rare Pediatric Disease PRV, adding non-dilutive capital to advance its clinical portfolio and growth plans.
Zacks

Advertisement|Remove ads.